CMPS Compass Pathways Plc
Company Analysis
Latest News
🟢 Compass Pathways rises 5.2% — Biotech Sector Surges on M&A Activity and Positive Clinical Trial Data
With Biotech (XBI) up 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector is experiencing a significant...
🔴 Compass Pathways falls 5.1% — Biotech Sector Declines Amid Broad Market Rotation
With Biotech (XBI) down 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector, as represented by the XBI...
🟢 Compass Pathways rises 4.0% — Biotech Sector Rallies on Strong IPO Debuts and M&A Activity
With Biotech (XBI) up 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector is experiencing a significant rally,...
🟢 Compass Pathways is trading 6.5% up in pre-market
Compass Pathways is trading at $12.22, up 6.50% versus the October 8 close, with no clear company-specific announcement identified to explain the pre-market...
🔴 Compass Pathways is trading 4.02% down today amid biotech losses and oil-fueled market concerns
Compass Pathways is trading at $11.22 (-4.02%), with broad risk-off pressure the likeliest backdrop; available sources do not establish a direct...
🔴 Compass Pathways is trading 4.37% down
Compass Pathways is trading 4.37% lower at $11.38, with no clear catalyst identified. - Search found no October 5 company announcement; the latest news was...
🟢 Compass Pathways is trading 4.03% up in pre-market — cause remains unclear
Compass Pathways is trading up 4.03% in pre-market at $12.38 on October 5, 2026; the cause of the gain remains unclear. - The company news page lists no...
🔴 Compass Pathways is trading 4.2% down — with no confirmed catalyst
Compass Pathways is trading 4.2% down at $11.91 on October 1, 2026, with no confirmed catalyst identified for the decline. - The latest substantial company...
🔴 Compass Pathways is trading 4.1% down — no confirmed catalyst
Compass Pathways is trading 4.1% down at $12.44 on September 30, 2026, with no clear catalyst identified. - The latest major company update was September 9...
🔴 Compass Pathways is trading 4.58% down today amid biotechnology-sector and macroeconomic pressure
Compass Pathways is trading at $13.12, down 4.58%, alongside a 2.04% decline in the biotechnology sector. - Broader markets are lower as higher Treasury...
🔴 Compass Pathways is trading 4.36% down today amid higher yields and weaker major indexes
Compass Pathways is trading 4.36% down at $14.14, with broader risk-off trading, higher yields and weaker major indexes appearing to be the primary...
🟢 Compass Pathways is trading 11.32% up today on biotech M&A optimism
Compass Pathways is trading 11.32% up at $15.36 as biotech shares strengthened broadly on improving industry outlook and M&A optimism. - Biotech ETF XBI is up...
🟢 Compass Pathways rises 6.9% — Biotech Sector Rallies on Strong Industry Outlook and M&A Optimism
With Biotech (XBI) up 2.5%, this looks like a sector-led move rather than a company-specific surprise. The biotechnology sector, as measured by the XBI ETF,...
🔴 Compass Pathways falls 5.2% — Biotech Sector Declines on Key Drug Trial Failure and Shifting Investor Sentiment
With Biotech (XBI) down 2.1%, this looks like a sector-led move rather than a company-specific surprise. The biotech sector, as measured by the XBI ETF, fell...
🔴 Compass Pathways is trading 6.06% down today as hotter-than-expected August PPI spurs risk-off selling
Compass Pathways is trading 6.06% down now at $14.25 amid broader risk-off selling following hotter-than-expected August producer-price inflation. - The S&P...
Compass Pathways Surges on Year-Long Depression Drug Data, but Can a Pre-Revenue Biotech Justify the Hype Before FDA Decision Day?
Shares of Compass Pathways (CMPS) jumped 10.4% to $15.50 on September 9, bucking a down day for U.S. stocks, after the company reported that patients in its...
🟢 Compass Pathways is trading 10.39% up today after positive 52-week COMP005 results showed second-dose benefit
Compass Pathways is trading 10.39% up at $15.50 after September 9, 2026, topline 52-week Phase 3 COMP005 results showed additional benefit from a second...
🟢 Compass Pathways is trading 5.2% up today after positive 52-week COMP005 trial results
Compass Pathways is trading at $14.78, up +5.24%, after announcing positive 52-week topline results from Part C of its Phase 3 COMP005 trial on September 9,...
🟢 Compass Pathways is trading 5.6% up today
Compass Pathways is trading $14.01, up 5.58%, with no reliable source attributing the rally to its latest announcements. - The company announced participation...
🟢 Compass Pathways is trading 6.75% up in pre-market — catalyst remains unclear
Compass Pathways is trading 6.75% up at $14.13 after no clear September 2, 2026 company-specific catalyst was identified. - The latest surfaced disclosures...